1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Authors

Showing 4 results for author "Ghayas Issa".

$Thumbnail for Revumenib Therapy Post-Hematopoietic Stem Cell Transplant for Patients With Relapsed/Refractory KMT2Ar, NPM1m, and NUP98r Acute Myeloid Leukemia: Post Hoc Analysis of Outcomes From AUGMENT-101$

AML - 632

Revumenib Therapy Post-Hematopoietic Stem Cell Transplant for Patients With Relapsed/Refractory KMT2Ar, NPM1m, and NUP98r Acute Myeloid Leukemia: Post Hoc Analysis of Outcomes From AUGMENT-101

Ghayas Issa

Poster Presenter: Ghayas Issa

$Thumbnail for Clinical Activity of Revumenib in Patients With Relapsed/Refractory NUP98-Rearranged Acute Leukemias$

AML - 723

Clinical Activity of Revumenib in Patients With Relapsed/Refractory NUP98-Rearranged Acute Leukemias

Ghayas Issa

Poster Presenter: Ghayas Issa

AML - 773

Efficacy of Revumenib in Acute Myeloid Leukemia Harboring NPM1-Mutated Co-Mutations: Post Hoc Analysis of AUGMENT-101

Ghayas Issa

Poster Presenter: Ghayas Issa

Thumbnail for ASC4FIRST Week (Wk) 144 Analysis: Continued Superior Efficacy and Favorable Safety of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed (ND) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

CML - 1050

ASC4FIRST Week (Wk) 144 Analysis: Continued Superior Efficacy and Favorable Safety of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed (ND) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Ghayas Issa

Poster Presenter: Ghayas Issa